Outsourcing in Clinical Trials Europe 2015May 19-20, 2015, Dusseldorf, Germany
This year sees the global Outsourcing in Clinical Trials series in Europe for the 6th year! Last year’s conference achieved record results, outselling in exhibition booth space 3 months ahead of the event, and with hundreds of industry leaders attending over the two days.
This year’s agenda is our most exciting yet, with cutting edge content to keep you at the forefront of developments in this sector. We have expanded the agenda to include more topics beyond the core Outsourcing issues, ranging from Operations, Finance issues, patient perspectives and Communications strategies. We are also including talks specifically tailored to different size companies so you can find content that is relevant to your company objectives and current projects.
We look forward to welcoming you to Düsseldorf in May!
Telephone: +44 207 936 6603
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within pharmaceutical, biotechnology, and virtual companies across Europe:CEOCMOCSOCFO
Israeli drugmaker Teva and Swedish pharmaceutical firm Active Biotech have enrolled the first patient in a Phase II trial (ARPEGGIO) of laquinimod, an investigational, oral, immune modulator, to treat primary progressive multiple sclerosis (PPMS).
US-based OncoMed Pharmaceuticals has started dosing in the randomised, double-blind, placebo-controlled Phase II clinical trial (YOSEMITE) of demcizumab (anti-DLL4, OMP-21M18) in patients with first-line metastatic pancreatic cancer.
Genzyme, a Sanofi company, has started an open label, single-arm Phase IIa clinical trial of GZ/SAR402671, a new oral substrate reduction therapy to treat patients with Fabry disease, a rare lysosomal storage disorder.
Merck and Pfizer have started an international Phase III trial (EMR 100070-004) of its investigational cancer immunotherapy avelumab in patients with stage IIIb/IV non-small cell lung cancer (NSCLC).
Bristol-Myers Squibb has stopped CheckMate -057, an open-label, randomised Phase III trial, which is evaluating Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non small cell lung cancer (NSCLC).
Germany-based Isarna Therapeutics has started the first-in-human Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting TGF-β2, for the treatment of advanced glaucoma.